We used LCP technology to design and synthesize a lipid core peptide vaccine with self-assembly and intramolecular adjuvant properties for the pre-expressed HSV-2 epitope,and evaluate the immune effect.In this study,LCPs were designed for two B cell epitopes gB466-473(EQDRKPRN)and gC216-223(GRTDRPSA),respectively named P1-(K)2-LC and P2-(K)2-LC,P2-LC.The other peptide including P1-P25,P1-P25-KLH,P2-P25,P2-P25-KLH.Mice in nine groups were intramuscularly immunized with 30 μg of each antigen per mousein the hind limbs with P1-(K)2-LC,P1-P25,P1-P25-KLH,and MF59 adjuvanted P1-P25,P2-(K)2-LC,P2-LC,P2-P25,P2-P25-KLH,and MF59 adjuvanted P2-P25 respectively,In peptide 1and peptide 2 experiment,mice were immunized for three times.Anti-P1-BSA or anti-P2-BSA IgG,IgG1,and IgG2a antibody titers were evaluated using ELISA and analyzed statistically in sera after each immunization.P1-(K)2-LC and P1-P25-KLH induced the highest IgG and IgG1 antibody titer.IgG and IgG1 titers induced by P2-(K)2-LC were higher than other groups after the second or third immunization.However,none peptide groups induced IgG2a antibody.In the T cell responses,CD4 and CD8 T cells isolated from immunized mice were stimulated with corresponding peptides and cytokines in the supernatant were detected.As a result,none of the cytokines were detectable.The HSV-2 virus neutralization activity of mouse serum after the last immunization was measured by a 50%plaque reduction assay.P1-(K)2-LC induced antisera performed a higher neutralization titer than the other three groups.In summary,this study designed,synthesized,and evaluated two lipid epitopes of B-cell epitopes that all showed good humoral immunity.P1-(K)2-LC and P2-LC could stimulate mice into producing specific antibodies that could neutralize HSV-2 infection in vitro.These results suggest that the lipid core peptide vaccine may be used for vaccine design against HSV-2.